Nayak Sanjay 4

4 · OCULAR THERAPEUTIX, INC · Filed Feb 17, 2026

AI-generated summary of this filing

Updated Feb 18, 2026

Ocular Therapeutix (OCUL) CSO Sanjay Nayak Sells 10,348 Shares

What Happened

Sanjay Nayak, Chief Strategy Officer of Ocular Therapeutix, sold 10,348 shares of common stock on 2026-02-12. The weighted-average sale price was $9.04 per share, resulting in proceeds of approximately $93,546.
This sale was not a discretionary trade: it was executed under a durable automatic sale instruction to effect a sell-to-cover election to satisfy tax withholding obligations related to restricted stock units that vested on 2026-02-11.

Key Details

Transaction date: February 12, 2026.
Price: Weighted average $9.04; individual trades ranged from $8.9950 to $9.0873 (report notes multiple transactions; reporting person can provide per-trade breakdown on request).
Shares sold: 10,348; proceeds ≈ $93,546.
Reason/footnote: Sell-to-cover for tax withholding tied to RSU vesting; sale executed under an automatic instruction adopted Feb 21, 2024 (not a discretionary sale).
Shares owned after transaction: Not specified in the provided filing excerpt.
Filing timing: Form 4 filed 2026-02-17 for a 2026-02-12 transaction — filed after the typical 2-business-day reporting window for Form 4.

Context

This was a tax-withholding sale (sell-to-cover) related to RSU vesting, which is generally routine and does not necessarily indicate insider sentiment about the company. Purchases typically carry more informational weight for investors than routine sales for tax purposes.

Form 4

Period: 2026-02-12

Chief Strategy Officer

Transactions

Footnotes (2)

[F1]Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 11, 2026. The sales do not represent a discretionary trade by the reporting person.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.9950 to $9.0873, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Signature

/s/ Todd Anderman, Attorney-in-Fact for Sanjay Nayak|2026-02-17

1 file